Expertise in
3
conditions

Dr. David B. Kudrow

Neurology
2001 Santa Monica Blvd, Suite 880w, 
Santa Moncia, CA 
 (2601.7 mi)
Expertise in
3
conditions
2001 Santa Monica Blvd, Suite 880w, 
Santa Moncia, CA 
 (2601.7 mi)
OverviewInsuranceLocationsClinical Research

Overview

David Kudrow is a Neurologist in Santa Moncia, California. Dr. Kudrow is highly rated in 3 conditions, according to our data. His top areas of expertise are Migraine, Headache, Cluster Headache, and Restless Legs Syndrome.

His clinical research consists of co-authoring 33 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Licenses
Psychiatry & Neurology in CA
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Locations

2001 Santa Monica Blvd, Suite 880w, Santa Moncia, CA 90404

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Participants With Painful Diabetic Peripheral Neuropathy
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Participants With Painful Diabetic Peripheral Neuropathy
Enrollment Status: Completed
Publish Date: February 26, 2025
Intervention Type: Other, Biological
Study Phase: Phase 3
Long-term, Prospective, Non-interventional, Extension of a Phase III, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety & Efficacy of Engensis (VM202) in Subjects With Painful Diabetic Peripheral Neuropathy
Long-term, Prospective, Non-interventional, Extension of a Phase III, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety & Efficacy of Engensis (VM202) in Subjects With Painful Diabetic Peripheral Neuropathy
Enrollment Status: Completed
Publish Date: February 25, 2025
Intervention Type: Drug, Genetic
Study Phase: Phase 3
An Adaptive, Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Engensis in Participants With Painful Diabetic Peripheral Neuropathy
An Adaptive, Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Engensis in Participants With Painful Diabetic Peripheral Neuropathy
Enrollment Status: Completed
Publish Date: January 20, 2025
Intervention Type: Biological, Other
Study Drug: Engensis
Study Phase: Phase 3
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2 Study of ABP-450 (prabotulinumtoxinA) Purified Neurotoxin Complex for the Prevention of Migraine Headache
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2 Study of ABP-450 (prabotulinumtoxinA) Purified Neurotoxin Complex for the Prevention of Migraine Headache
Enrollment Status: Completed
Publish Date: September 04, 2024
Intervention Type: Drug
Study Drug: ABP-450
Study Phase: Phase 2
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
Enrollment Status: Completed
Publish Date: June 28, 2024
Intervention Type: Drug
Study Drugs: Galcanezumab, Rimegepant
Study Phase: Phase 4
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Prospective, Randomized, Vehicle-Controlled, Double-Blind, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of B244 Delivered as an Intranasal Spray for Preventive Treatment in Subjects With Episodic Migraine
A Prospective, Randomized, Vehicle-Controlled, Double-Blind, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of B244 Delivered as an Intranasal Spray for Preventive Treatment in Subjects With Episodic Migraine
Enrollment Status: Completed
Publish Date: October 04, 2022
Intervention Type: Biological
Study Phase: Phase 2
Randomized, Double-Blind, Multi-Center, Parallel-Group Comparison of the Efficacy and Safety of the C213 (Zolmitriptan Microneedle System) to Placebo for the Acute Treatment of Cluster Headaches
Randomized, Double-Blind, Multi-Center, Parallel-Group Comparison of the Efficacy and Safety of the C213 (Zolmitriptan Microneedle System) to Placebo for the Acute Treatment of Cluster Headaches
Enrollment Status: Completed
Publish Date: June 14, 2022
Intervention Type: Drug
Study Drug: C213 Microneedle System
Study Phase: Phase 2/Phase 3
A Phase 4 Single-Blind Study of Gastrointestinal Transit Time in Adult Patients With Migraine Before and After Initiation of a mAb CGRP Antagonist
A Phase 4 Single-Blind Study of Gastrointestinal Transit Time in Adult Patients With Migraine Before and After Initiation of a mAb CGRP Antagonist
Enrollment Status: Completed
Publish Date: March 22, 2022
Intervention Type: Drug
Study Phase: Phase 4
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of : Galcanezumab (LY2951742) With a Long-Term Open-Label Extension in Patients With Chronic Cluster Headache
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of : Galcanezumab (LY2951742) With a Long-Term Open-Label Extension in Patients With Chronic Cluster Headache
Enrollment Status: Completed
Publish Date: August 25, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open Label, Multicenter Study Evaluating the Imaging Characteristics of a Follow up 18F-AV-1451 Scan in Subjects That Participated in the Confirmatory Cohort of 18F-AV-1451-A05
An Open Label, Multicenter Study Evaluating the Imaging Characteristics of a Follow up 18F-AV-1451 Scan in Subjects That Participated in the Confirmatory Cohort of 18F-AV-1451-A05
Enrollment Status: Completed
Publish Date: August 24, 2020
Intervention Type: Drug, Procedure
Study Phase: Phase 2
A Long-Term, Open-Label Study to Evaluate the Safety of M207 (Zolmitriptan Intracutaneous Microneedle System) in the Acute Treatment of Migraine
A Long-Term, Open-Label Study to Evaluate the Safety of M207 (Zolmitriptan Intracutaneous Microneedle System) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: August 19, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Enrollment Status: Completed
Publish Date: July 08, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
Enrollment Status: Completed
Publish Date: September 23, 2019
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Cluster Headache
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Cluster Headache
Enrollment Status: Completed
Publish Date: September 09, 2019
Intervention Type: Drug
Study Phase: Phase 3
Randomized, Double-blind, Multi-center, Parallel-group, Dose-ranging Comparison of the Safety and Efficacy of the ZP-Zolmitriptan Intracutaneous Microneedle Systems to Placebo for the Acute Treatment of Migraine
Randomized, Double-blind, Multi-center, Parallel-group, Dose-ranging Comparison of the Safety and Efficacy of the ZP-Zolmitriptan Intracutaneous Microneedle Systems to Placebo for the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: March 13, 2018
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
View 16 Less Clinical Trials

33 Total Publications

Safety of Rimegepant in Adults with Migraine and Anxiety, Depression, or Using Antidepressants: Analysis of a Multicenter, Long-Term, Open-Label Study.
Safety of Rimegepant in Adults with Migraine and Anxiety, Depression, or Using Antidepressants: Analysis of a Multicenter, Long-Term, Open-Label Study.
Journal: Pain and therapy
Published: August 23, 2024
Similar Doctors
Expertise in
22
conditions
Dr. Timothy Cloughesy
Neurology | Hematology Oncology
Expertise in
22
conditions
Dr. Timothy Cloughesy
Neurology | Hematology Oncology

The Regents Of The University Of California

150 Medical Plz, 
Los Angeles, CA 
 (3.2 mi)
310-825-9989
Languages Spoken:
English
Offers Telehealth

Timothy Cloughesy is a Neurologist and a Hematologist Oncology provider in Los Angeles, California. Dr. Cloughesy is highly rated in 22 conditions, according to our data. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Expertise in
50
conditions
Dr. Susan L. Perlman
Neurology
Expertise in
50
conditions
Dr. Susan L. Perlman
Neurology

The Regents Of The University Of California

150 Medical Plz, 
Los Angeles, CA 
 (3.2 mi)
310-825-9989
Languages Spoken:
English
Offers Telehealth

Susan Perlman is a Neurologist in Los Angeles, California. Dr. Perlman is highly rated in 50 conditions, according to our data. Her top areas of expertise are Spinocerebellar Ataxia, Friedreich Ataxia, Drug Induced Dyskinesia, and Olivopontocerebellar Atrophy.

Expertise in
25
conditions
Dr. Santosh Kesari
Neurology
Expertise in
25
conditions
Dr. Santosh Kesari
Neurology

Providence Saint Johns Medical Foundation

11645 Wilshire Blvd, Suite 600, 
Los Angeles, CA 
 (1.8 mi)
310-477-5558
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Santosh Kesari is a Neurologist in Los Angeles, California. Dr. Kesari is highly rated in 25 conditions, according to our data. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Gliomatosis Cerebri, and Tissue Biopsy.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile